Institutional Activity Shifts as Renaissance Technologies Trims Mereo BioPharma Stake Renaissance Technologies LLC reduced its holdings in Mereo BioPharma Group by nearly 9% in the fourth quarter, selling 115,900 shares. Despite this, institutional investors collectively own over 62% of the company. Analyst sentiment remains positive, with multiple "buy" ratings and an average price target of $7.71, signaling continued market confidence.123